Abstract
The need of using chemically modified siRNA agents for gene silencing continuously increasing as appropriate chemical modification improves their specificity, nuclease stability, potency, and in vivo cellular delivery. The future success of RNAi technology also depends on identifying drug carriers that are non-toxic and tissue-specific in directing the RNAi agents to the desired locations in a cost effective fashion. This review will cover recently reported chemically modified siRNA agents for improving specificity and potency of mRNA knockdown, their nuclease stability, cellular uptake and improved biodistribution. In addition to the chemical modifications and their biological impact, this review also focuses on the in vivo RNAi delivery techniques.
Keywords: Chemical modification, siRNA, RNA interference, RNAi agents, Gene-silencing, miRNA, In vivo RNAi
Current Bioactive Compounds
Title: Chemical Modifications of Synthetic RNAi Agents and in vivo Delivery Techniques
Volume: 4 Issue: 1
Author(s): Anilkumar R. Kore and Lance P. Ford
Affiliation:
Keywords: Chemical modification, siRNA, RNA interference, RNAi agents, Gene-silencing, miRNA, In vivo RNAi
Abstract: The need of using chemically modified siRNA agents for gene silencing continuously increasing as appropriate chemical modification improves their specificity, nuclease stability, potency, and in vivo cellular delivery. The future success of RNAi technology also depends on identifying drug carriers that are non-toxic and tissue-specific in directing the RNAi agents to the desired locations in a cost effective fashion. This review will cover recently reported chemically modified siRNA agents for improving specificity and potency of mRNA knockdown, their nuclease stability, cellular uptake and improved biodistribution. In addition to the chemical modifications and their biological impact, this review also focuses on the in vivo RNAi delivery techniques.
Export Options
About this article
Cite this article as:
Kore R. Anilkumar and Ford P. Lance, Chemical Modifications of Synthetic RNAi Agents and in vivo Delivery Techniques, Current Bioactive Compounds 2008; 4 (1) . https://dx.doi.org/10.2174/157340708784533375
DOI https://dx.doi.org/10.2174/157340708784533375 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Fluorescent SNAP-Tag Galectin Fusion Proteins as Novel Tools in Glycobiology
Current Pharmaceutical Design Src Inhibitors and Angiogenesis
Current Pharmaceutical Design Genetics of Bladder Malignant Tumors in Childhood
Current Genomics Diagnostic Capabilities of MRI Versus 18F FDG PET-CT in Postoperative Patients with Thyroglobulin Positive, 131I-negative Local Recurrent or Metastatic Thyroid Cancer
Current Medical Imaging Synthesis and <i>In Silico</i> Studies of C-4 Substituted Coumarin Analogues as Anticancer Agents
Current Computer-Aided Drug Design Tumor Necrosis Factor: How to Make a Killer Molecule Tumor-Specific?
Current Cancer Drug Targets Doxsaliform: A Novel N-Mannich Base Prodrug of a Doxorubicin Formaldehyde Conjugate
Letters in Drug Design & Discovery Therapeutic Approaches for Dominant Muscle Diseases: Highlight on Myotonic Dystrophy
Current Gene Therapy Chemical Advances in Therapeutic Application of Exosomes and Liposomes
Current Medicinal Chemistry Chemical Modifications and Biological Activities of Polysaccharides
Current Drug Targets Copper Compounds in Anticancer Strategies
Current Medicinal Chemistry Recent Advances in Targeted Anti-Vasculature Therapy: The Neuroblastoma Model
Current Drug Targets The PIK3CA Gene as a Mutated Target for Cancer Therapy
Current Cancer Drug Targets Biomacromolecule-Functionalized Nanoparticle-Based Conjugates for Potentiation of Anticancer Therapy
Current Cancer Drug Targets Biosafety of Herpesvirus Vectors
Current Gene Therapy Preclinical Evaluation of a Zinc Finger Inhibitor Targeting Lentivirus Nucleocapsid Protein in SIV-Infected Monkeys
Current HIV Research Immunomodulatory Activity of MicroRNAs: Potential Implications for Multiple Myeloma Treatment
Current Cancer Drug Targets Chlorophylls and their Derivatives Used in Food Industry and Medicine
Mini-Reviews in Medicinal Chemistry Intracellular Logistics of BST-2/Tetherin
Current HIV Research Potential of DNMT and its Epigenetic Regulation for Lung Cancer Therapy
Current Genomics